Skip to Main Content
  1. Home
  2. SEER Data & Software
  3. SEER Incidence Database
  4. Specialized Databases
  5. Available Databases
  6. Prostate Cancer with Decipher Prostate Genomic Classifier Database

Prostate Cancer with Decipher Prostate Genomic Classifier Database

* indicates required field

Access the Database

To request access this specialized database, you must already have access to the latest SEER Reasearch Plus Data.

  • If you do not have access to SEER Research Plus Data, first request Access to the SEER data.
  • If you already have access, use the request options below.

Required Information:

  • Contact Information
  • SEER*Stat Username
  • Purpose and Analysis Plan

Submit a Request

This database is available only to U.S. based researchers affiliated with U.S. institutions.

The database includes Decipher Prostate Genomic Classifier (GC)-related variables for prostate cancer cases. These data were obtained through a linkage of prostate cancer cases from the SEER registries to Decipher Prostate GC test orders and results provided by Veracyte. The following SEER registries did not participate in the linkage: Illinois State Cancer Registry, New Jersey State Cancer Registry, Texas Cancer Registry (these 3 registries were not SEER registries at the time of the linkage) and Alaska Native Tumor Registry. Details about the linkage methods can be found in a recent journal article (1).

Approximately 561,000 prostate cancer cases diagnosed from 2010 to 2018 were included, of which 15,309 cases were linked to Decipher Prostate GC test results. The Decipher Prostate GC performed on radical prostatectomy specimen has been available since 2013 and Decipher Prostate GC on biopsy tissue since 2016. Although a majority of linked prostate cases have only one test, up to four tests could be available per patient.

Variable Definitions

The specialized Decipher Prostate GC fields are described below:

Variable Name in SEER*Stat Values Description
Decipher Prostate GC Type of Test1 [through 4] (2010-2018)
  1. Decipher Biopsy
  2. Decipher Radical Prostatectomy
 Indicates the type of test based on the source of the specimen: biopsy or radical prostatectomy
Decipher Prostate GC score Test1 [through 4] (2010-2018) 0.01-1.00 Decipher Prostate Genomic Classifier Score reported on a scale of 0–1
Decipher Prostate GC risk group Test1 [through 4] (2010-2018)
  1. Lower <0.45;
  2. Average 0.45-0.60;
  3. Higher >0.60
 Risk categories: Lower-GC score<0.45; Average-GC score 0.45-0.60; High-GC score >0.60
Decipher Prostate GC Test1 [through 4] Date Year (2010-2018) 2013-2020 Year in which Test was performed
Decipher Prostate GC Test1 [through 4] Date Month (2010-2018) Jan-Dec Month in which Test was performed; Not released in case listing
Decipher Prostate GC Months Since Diagnosis Test1 [through 4] (2010-2018)

0+

 Number of months between diagnosis and Test

In addition to the Decipher Prostate GC fields, these data also include the four specialized fields from the Prostate Cancer with Additional Treatment and Risk Stratification Fields specialized database:

  1. Watchful waiting recode (2010+)
  2. TNM Clin T (2016-2017)
  3. Prostate Cancer Initial Treatment recode (2010+)
  4. Prostate Cancer NCCN Risk Group recode (2010+)

Database Details

There is currently one Prostate Cancer with Decipher Prostate Genomic Classifier database available to approved requesters. It is identical to the SEER Research Plus database other than the specialized fields described above.

SEER 17 (excl AK)

  • Available in the Frequency, Survival, and Case listing sessions in SEER*Stat.
  • November 2023 data submission with all tumor records from 2000 to 2021 for the included registries, but the Decipher Prostate GC fields are available for tested patients diagnosed from 2010 to 2018.
  • It does not include Alaska Native Tumor Registry data.
  • The number of patients with at least one linked test result is 8,463.

Several additional versions of this database will become available soon (e.g., including SEER 22 registries as well as versions with census tract attributes. Some of these additional databases may require IRB approval. Periodic linkages have been conducted to update the database).

Data Limitations and Analytical Considerations

The SEER treatment data is limited to the first course of treatment, therefore it does not have the full sequence of treatments (refer to the Treatment Data Limitations for more information).

Reference

  1. Petkov VI, Byun JS, Ward KC, Schussler NC, Archer NP, Bentler S, Doherty JA, Durbin EB, Gershman ST, Cheng I, Insaf T, Gonsalves L, Hernandez BY, Koch L, Liu L, Monnereau A, Morawski BM, Schwartz SM, Stroup A, Wiggins C, Wu XC, Bonds S, Negoita S, Penberthy L. Reporting tumor genomic test results to SEER registries via linkages. J Natl Cancer Inst Monogr. 2024 Aug 1;2024(65):168-179. [PubMed Abstract]